Loading…
Loading…
FLHLF (Filament Health Corp.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
FLHLF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for FLHLF and 80,000+ other tickers.
See exactly how FLHLF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for FLHLF and 80,000+ other tickers.
Filament Health Corp. is a pioneering company dedicated to the discovery and extraction of natural psychedelic compounds. Its operations encompass the cultivation of psychedelic plants, genetic research, advanced extraction methodologies, and the conduct of internal clinical trials. Furthermore, the firm licenses its intellectual property and potential drug substances to pharmaceutical developers, scientific researchers, and other authorized entities. The company's principal office is located in Vancouver, Canada.
Establishes a vertically integrated platform spanning pharmaceutical-grade botanical drug development and global consumer distribution Adds Filament's extensive intellectual property portfolio, including 70+ patents and proprietary extraction technologies Leverages Health Canada Dealer's License and FDA-aligned clinical development pathways, including IND-enabled activities Positions the Company at the forefront of the rapidly emerging regulated psychedelic medicine industry Advances clinical pipeline, including PEX010, while expanding access to natural psilocybin products globally Establishes a regulated pipeline of psychedelic compounds, including ibogaine, MDMA, and psilocybin, supporting next-generation drug discovery and IND-enabled clinical development within compliant frameworks Toronto, Ontario--(Newsfile Corp. - April 30, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Filament Health Corp. (OTC: FLHLF) ("Filament") are pleased to announce, further to their joint press releases dated March 10, 2026 (the "March 10 Release"), March 23, 2026, April 27, 2026 and April 29, 2026, that effective April 29, 2026, Red Light has acquired all the issued and outstanding common shares of Filament ("Filament Shares"), pursuant to a statutory plan of arrangement (the "Arrangement" or the "Transaction") under the Business Corporations Act (British Columbia). Capitalized terms not otherwise defined herein have the meanings attributed to them in the March 10 Release.
Toronto, Ontario--(Newsfile Corp. - April 29, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Filament Health Corp. (OTC: FLHLF) ("Filament") are pleased to announce that, further to their joint press release dated March 10, 2026, March 23, 2026 and April 27, 2026, that the Supreme Court of British Columbia has issued a final order (the "Final Order") approving the previously announced acquisition by Red Light of all the issued and outstanding common shares of Filament, pursuant to a statutory plan of arrangement (the "Arrangement") under the Business Corporations Act (British Columbia). Completion of the Arrangement remains subject to customary conditions and certain regulatory approvals.
Toronto, Ontario--(Newsfile Corp. - April 27, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light") and Filament Health Corp. (OTC: FLHLF) ("Filament") are pleased to announce that, further to their joint press release dated March 10, 2026 and March 23, 2026, Filament's shareholders (the "Filament Shareholders") have approved each of the matters voted on at the Filament annual general and special meeting ("Filament Meeting") held on April 24, 2026, including approving the proposed plan of arrangement under the Business Corporations Act (British Columbia) (the "Arrangement") with Red Light, which will result in the acquisition of all the issued and outstanding common shares of Filament ("Filament Shares") by Red Light. As disclosed in Filament's management information circular dated April 2, 2026 (the "Filament Circular"), the special resolution approving the Arrangement (the "Arrangement Resolution") required the approval of: (i) 66⅔% of the votes cast by Filament Shareholders present in person or represented by proxy at the Filament Meeting; and (iii) a simple majority of votes cast by Filament Shareholders present in person or represented by proxy at the Filament Meeting after excluding votes cast by Filament Shareholders who are required to be excluded to obtain "minority approval" in accordance with Section 8.1 of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101").
Toronto, Ontario--(Newsfile Corp. - March 23, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Filament Health Corp. (OTC: FLHLF) ("Filament") today announced that, further to the joint press release dated March 10, 2026, the Supreme Court of British Columbia issued an interim order (the "Interim Order") in connection with the previously announced acquisition by Red Light of all the issued and outstanding common shares of Filament (the "Filament Shares"), pursuant to a statutory plan of arrangement (the "Arrangement") under the Business Corporations Act (British Columbia). Among other things, the Interim Order authorizes Filament to call, hold and conduct an annual general and special meeting (the "Meeting") of the holders of Filament Shares (the "Filament Shareholders") on April 24, 2026 at 8:00 a.m.
Whole leaf coca extract under evaluation is Magdalena's drug candidate for post-GLP-1 weight loss management SAN FRANCISCO, CA / ACCESS Newswire / March 16, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Magdalena Biosciences ("Magdalena"), a US-based joint venture formed by Jaguar and Canada-based Filament Health Corp. (OTC:FLHLF) ("Filament"), has initiated a preclinical study evaluating the effectiveness of a whole leaf coca extract for appetite suppression. The coca leaf extract is Magdalena's drug candidate for post-GLP-1 weight loss management.